Retinitis pigmentosa is a group of inherited disorders in which the light-sensing cells of the retina gradually degenerate. The rod cells, which handle vision in dim light and around the periphery, are affected first — which is why the earliest symptoms are difficulty seeing at night and a narrowing field of vision.

It is not a single disease. More than a hundred genes have been associated with retinitis pigmentosa, and the gene involved influences the age at onset, the rate of change and the pattern of vision loss.

How it typically presents

Onset is usually in childhood, adolescence or early adulthood, though some forms present later.

  • Night blindness is characteristically the first symptom — difficulty adapting when moving from a lit room into darkness, or trouble navigating in dim conditions.
  • Peripheral field loss follows, often gradually enough that patients adapt without registering it, and is sometimes first noticed as bumping into objects or difficulty in crowds.
  • Reduced contrast sensitivity and glare sensitivity, with bright light causing discomfort and slow recovery.
  • Central vision is generally preserved until later stages, so acuity on a chart can remain good while the usable field is substantially reduced.

This dissociation — good measured acuity with a constricted field — is characteristic, and it means chart vision alone significantly understates the functional impact.

Confirming the diagnosis

Examination shows characteristic changes including pigment deposits in the peripheral retina, narrowed retinal vessels and a pale optic disc, though these develop over time and may be subtle early.

  • Visual field testing measures the extent of the remaining field and is the principal way progression is tracked over years.
  • Electroretinography (ERG) measures the electrical response of the retina to light and can detect reduced rod function before changes are visible on examination.
  • Optical coherence tomography shows thinning of the photoreceptor layer and detects macular swelling, which occurs in a proportion of patients and is treatable.
  • Fundus autofluorescence often reveals a ring pattern that corresponds to the boundary of surviving function and is useful for tracking change.

Genetic testing and family implications

Genetic testing is now a standard part of the evaluation, and its role has changed from academic interest to practical consequence.

Identifying the causative gene can clarify the expected course, establish the inheritance pattern — autosomal dominant, autosomal recessive, X-linked or syndromic — and inform family members about their own risk. It also determines eligibility for gene-specific treatments and for clinical trials, several of which recruit only patients with particular genetic variants.

Some forms of retinitis pigmentosa occur as part of a syndrome affecting other organs, most commonly Usher syndrome, which involves hearing loss. Genetic testing can identify these, which matters because they warrant evaluation beyond the eye.

Genetic counseling is recommended alongside testing, so that results are interpreted properly and the implications for family members are discussed with appropriate support.

What management involves

There is no treatment that halts the underlying degeneration in most forms of retinitis pigmentosa, and patients are best served by honesty about that. There is nonetheless a good deal that is done:

  • Treating complications. Macular swelling occurs in a proportion of patients and often responds to treatment; cataract develops earlier than average and its removal can meaningfully improve vision. Both are worth identifying, and both are missed if patients stop attending because the underlying condition is untreatable.
  • Gene-specific therapy. A treatment exists for retinal dystrophy caused by biallelic RPE65 mutations, which affects a small subset of patients. This is one of the practical reasons genetic testing is worthwhile.
  • Clinical trials. Inherited retinal disease is an active research area, and eligibility frequently depends on the specific genetic diagnosis.
  • Protective measures. Sunglasses with ultraviolet protection are commonly advised, and tinted lenses can reduce glare and improve contrast.
  • Supplementation. Vitamin A and related supplementation has been studied with mixed conclusions, is not appropriate for all genetic subtypes, and can be harmful in some. It should only be considered under the direction of a physician who knows your genetic diagnosis.

Low vision support and daily function

Low vision rehabilitation is central rather than supplementary in retinitis pigmentosa, and referral is worth arranging early rather than waiting until vision is severely limited.

  • Orientation and mobility training, which addresses the field loss that is the main functional problem
  • Magnification and electronic reading aids as central vision becomes involved
  • Lighting and contrast strategies, and filters to manage glare
  • Screen reader software, voice assistance and accessible technology
  • Assessment for driving, and planning for transport where driving is no longer appropriate
  • Connection to patient organizations and support networks

Regular monitoring continues regardless, both to track the field and to catch the treatable complications that arise along the way.

Retinitis pigmentosa: questions and answers

Most people with retinitis pigmentosa retain some vision throughout life, and complete loss of all light perception is not the usual outcome. The course varies substantially with the genetic subtype, which is one reason genetic testing is useful for understanding what to expect. General predictions are unreliable at an individual level.

Progression is typically slow, measured over years and decades rather than months, and it varies widely between genetic subtypes and between individuals. Serial visual field testing measures your own rate rather than relying on averages.

In most cases yes. It can establish the inheritance pattern for your family, identify syndromic forms that need attention beyond the eye, determine eligibility for gene-specific treatment and clinical trials, and give a clearer sense of the likely course. Genetic counseling should accompany it.

That depends on the inheritance pattern, which genetic testing identifies. Autosomal dominant, autosomal recessive and X-linked forms carry very different risks to children, and these are best discussed with a genetic counselor who has your specific result rather than estimated in general terms.

The evidence is mixed, the benefit is modest where it exists, and vitamin A is not appropriate for all genetic subtypes — in some it may be harmful. High-dose vitamin A also carries risks to the liver and is not advised in pregnancy. It should only be taken under the direction of a physician who knows your genetic diagnosis.

Because several of the things that reduce vision in retinitis pigmentosa are treatable — macular swelling and cataract in particular — and because eligibility for trials and gene-specific treatments changes over time. Monitoring also tracks the field, which informs decisions about driving, mobility training and support.

Retinitis pigmentosa evaluation and monitoring

Retina Macula Institute of Arizona provides retinal imaging, field testing and ongoing monitoring for inherited retinal disease in Scottsdale. Call (602) 613-5473 or contact us.